- Home
- ARCO vs MESO Comparison
ARCO vs MESO Comparison
Compare ARCO & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARCO
- MESO
- Stock Information
- Founded
- ARCO 2007
- MESO 2004
- Country
- ARCO Uruguay
- MESO Australia
- Employees
- ARCO N/A
- MESO N/A
- Industry
- ARCO Restaurants
- MESO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ARCO Consumer Discretionary
- MESO Health Care
- Exchange
- ARCO Nasdaq
- MESO Nasdaq
- Market Cap
- ARCO 1.5B
- MESO 1.7B
- IPO Year
- ARCO 2011
- MESO N/A
- Fundamental
- Price
- ARCO $7.58
- MESO $11.82
- Analyst Decision
- ARCO Buy
- MESO Buy
- Analyst Count
- ARCO 1
- MESO 4
- Target Price
- ARCO $12.00
- MESO $18.00
- AVG Volume (30 Days)
- ARCO 2.3M
- MESO 223.6K
- Earning Date
- ARCO 05-14-2025
- MESO 02-26-2025
- Dividend Yield
- ARCO 3.21%
- MESO N/A
- EPS Growth
- ARCO N/A
- MESO N/A
- EPS
- ARCO 0.71
- MESO N/A
- Revenue
- ARCO $4,470,162,000.00
- MESO $5,670,000.00
- Revenue This Year
- ARCO $6.66
- MESO $228.57
- Revenue Next Year
- ARCO $8.58
- MESO $356.77
- P/E Ratio
- ARCO $10.64
- MESO N/A
- Revenue Growth
- ARCO 3.19
- MESO N/A
- 52 Week Low
- ARCO $6.66
- MESO $5.78
- 52 Week High
- ARCO $11.49
- MESO $22.00
- Technical
- Relative Strength Index (RSI)
- ARCO 49.97
- MESO 49.97
- Support Level
- ARCO $6.88
- MESO $10.11
- Resistance Level
- ARCO $7.77
- MESO $10.89
- Average True Range (ATR)
- ARCO 0.35
- MESO 0.76
- MACD
- ARCO 0.05
- MESO 0.29
- Stochastic Oscillator
- ARCO 82.43
- MESO 93.25
About ARCO Arcos Dorados Holdings Inc. Shares
Arcos Dorados Holdings Inc operates McDonald's-branded restaurants in approximately 20 countries and territories in Latin America and the Caribbean. It functions through two sources which include company-operated restaurants and franchised restaurants segment. Their menu includes hamburgers, McNuggets, salad, sandwiches, french fries and others.
About MESO Mesoblast Limited
Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.